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Abstract
Background: Perinatal morbidity and mortality remain significant public health issues globally, with enduring
impact on the health and well-being of women and their families. Pregnant women who adopt, practice and
maintain healthy behaviours can potentially improve the health of themselves and their babies. Mobile applications
are an increasingly popular mode of accessing, storing and sharing health information among pregnant women.
The main objective of this review is to evaluate the effects of mobile application interventions during pregnancy on
maternal behaviour and associated maternal and infant outcomes.
Methods: This review will include randomised and non-randomised studies which tested use of mobile applications
designed to improve either maternal knowledge or behaviours to address known risk factors associated with adverse
perinatal health outcomes. This review will include studies which included pregnant women and/or women during
birth. The search strategy will utilise a combination of keywords and MeSH terms. Literature databases such as PubMed,
Embase, The Cochrane Library, CINAHL and WHO Global Health Library will be searched. Two reviewers will
independently screen retrieved citations to determine if they meet inclusion criteria. Studies will be selected
that provide information about interventions commenced in early pregnancy, late pregnancy or labour.
Comparisons to be made include mobile applications versus interventions relying on paper-based or text-messaging-
based communication; interpersonal communication such as face-to-face or telephone conversation; and no
intervention or standard care. Quality assessment of included randomised studies will utilise established guidelines
provided in the Cochrane Handbook for Systematic Reviews of Interventions. Quality assessment of non-randomised
studies will be based on the Risk of Bias in Non-randomised Studies-of Interventions (ROBINS-I) assessment tool. Quality of
the evidence will be evaluated using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE)
approach. Separate comparisons and analyses for primary and secondary outcomes will be performed. Results of the
review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.
Discussion: This systematic review will identify and synthesize evidence about the effect of interventions delivered
through mobile applications on influencing maternal behaviour and improving perinatal health outcomes.
Systematic review registration: PROSPERO CRD42016037344.
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Background
Perinatal morbidity and mortality remain significant
public health issues globally, with enduring impact on
the health and well-being of women and their families.
Pregnant women who adopt, practice and maintain
healthy behaviours can potentially improve the health of
themselves and their babies. Some maternal risk factors
for adverse perinatal health outcomes, such as obesity,
smoking, substance use, hypertension, diabetes, adequate
nutrition [1–3] and maternal perception of decreased
fetal movement [4], may be modifiable through changes
in maternal behaviour. These risk factors also have an
association with increased rates of stillbirth, pre-term
birth, low birthweight and small for gestational age ba-
bies, and emergency caesarean section [5].
Health communication methods such as face-to-face
education, pamphlets, audio-visual training clips and
mass media have been employed for decades to encourage
healthy behaviours among pregnant women. However,
women are increasingly turning to digital sources of infor-
mation during pregnancy [6], and may prefer these modal-
ities over traditional, paper-based formats [7].
The emergence of mobile health modalities extends
the opportunity to reach, teach, connect, motivate, and
empower individuals to address specific health concerns
[8]. Mobile phone-based interventions represent a shift
in health communication modalities to a dynamic,
interactive environment that can include verbal, vocal,
and visual messages [9]. These interventions provide
individual-level support to pregnant women, due to
their popularity, mobility, technological capabilities,
and availability [10]. Broadly, mobile health strategies
have the potential to improve perinatal outcomes by
improving access to health information, modifying de-
mand for quality services, and enabling the provision
of targeted care [11].
In particular, mobile applications may assist women
with tools to support healthier lifestyles and strengthen
informed decision-making. Mobile applications (“apps”)
are computer programs designed to run on mobile
devices such as smartphones and tablet computers. Apps
became widely available for consumer download from
2008, with the launch of “app marketplaces” tailored to
the user’s mobile operating system [12]. There are now
over 100,000 health and medical apps available for use
by lay people and healthcare workers, and apps directed
at pregnancy constitute a major genre [13, 14]. These
applications can include health information, motiv-
ational messages, monitoring, and behaviour change
tools, with content tailored by demographics such as
maternal age, gestational age, health issues or other
known risk factors, cultural affiliation, or language. Apps
have become a popular modality to access, store, and
share health information.
Recent studies have found that pregnant women are
seeking mobile apps to provide information, to monitor
fetal development and changes in their own bodies and
to provide reassurance [6, 15–17]. Pregnant women may
also feel heightened support for informed decision-
making and sense of control, using a familiar device to
access, store and share information. One Australian
study found that 75% of pregnant women had down-
loaded at least one pregnancy app, and the majority of
these women used one of these apps at least once per
week [15].
The number of pregnant women and women of
childbearing age already using pregnancy-related mo-
bile applications to access information, track individual
health indicators and assist in decision-making is rising
exponentially. Collectively, pregnancy apps available
through app stores GooglePlay and iTunes have been
downloaded hundreds of millions of times and are an
integral source of information for many pregnant
women, particularly in high-income countries [18].
Health systems and maternity care facilities are ques-
tioning whether and how to integrate these patient
support modalities to improve outcomes for mothers and
newborns. However, limited evidence exists to support the
value of mobile applications, compared to other commu-
nication methods, in terms of maternal behaviour change
or perinatal health outcomes. Similarly, few studies have
reviewed the content delivered to pregnant women
through mobile applications, and whether content is
accurate, addresses specific need of women with high-risk
pregnancies or pre-existing medical conditions [19].
Mobile phone-based applications offer a new frontier
to test theories of behaviour change, health promotion
and health care-seeking behaviour. To date, most pub-
lished studies of mobile phone interventions have ana-
lysed text messaging as the primary mode of health
communication [20, 21], as opposed to an interactive
mobile application. Investigation of the effectiveness of
mobile applications for provision of perinatal health
information, and their impact on maternal behaviour
and associated maternal and infant outcomes, is particu-
larly topical.
Aim
This review aims to assess the effects of mobile applica-
tion interventions during pregnancy on influencing
healthy maternal behaviour and improving perinatal
health outcomes, compared with interventions using
other communication modalities or with standard care.
Methods
Protocol
This systematic review protocol has been developed
based on Preferred Reporting Items for Systematic
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Reviews and Meta-Analysis Protocols (PRISMA-P)
guidelines for reporting systematic reviews evaluating
health care interventions [22, 23]. A PRISMA-P checklist
file is attached (Additional file 1).
Eligibility criteria
Studies will be selected according to the criteria outlined
below.
Participants
Included studies will involve women during any stage of
pregnancy, or labour.
Interventions
Studies assessing the effects of mobile application-based
interventions designed to influence maternal knowledge
or behaviour during pregnancy will be considered for
inclusion. Mobile application-based interventions will be
included if they provide general information for preg-
nant women, or focus on a specific maternal risk factor
or perinatal outcome. There will be no restrictions on
who has sponsored the intervention; for example, mobile
apps developed commercially will be eligible, as will
mobile apps developed by hospitals, health systems or
other organisations.
Studies will be excluded if they fulfil any of the following
criteria:
▪ Do not utilise a mobile application
▪ Mobile phone is used solely for telephone conversations
or text messaging
▪ Do not report on a maternal or infant health outcome
▪ Do not describe mobile application interventions for
pregnant women (as opposed to health care workers,
clinicians, partners, etc.)
▪ Study focuses on physical effects of mobile phone
usage (such as radiation) during pregnancy
Comparators
The following comparisons will be made:
1. Mobile health application versus paper-based or
text-messaging-based communications
2. Mobile health application versus interpersonal
communication modes (face-to-face or telephone
conversation)
3. Mobile health application versus no specified
intervention, or standard care.
Outcomes
Primary outcomes
Change in maternal behaviours (as defined by trial
authors), by intervention goals; for example, adoption
of healthier lifestyles, smoking cessation, increased
physical activity, weight control, glucose control,




▪ Major adverse maternal outcome (composite of
death, admission to intensive care unit or near-miss





▪ Gestational diabetes mellitus (GDM)
▪ Emergency caesarean birth
▪ Successful initiation of breastfeeding
▪ Maternal knowledge (about the health topic (s)
that is/are the target of the intervention)
▪ Maternal general health (as defined by standardised
measures such as general health questionnaires)
▪ Maternal evaluation of the intervention (as
reported by the trial)
▪ Maternal psychosocial outcomes, such as
satisfaction, self-efficacy or anxiety (as measured
by any validated, standard instrument)
▪ Maternal-infant bonding (as reported by the trial)
▪ Maternal perception of communication with
health care providers
▪ Health service utilisation (antenatal care
attendance, maternal antenatal admission, length




▪ Small for gestational age (SGA)
▪ Large for gestational age (LGA)
▪ Preterm birth (before 32 weeks)
▪ Gestational age at birth
▪ Caesarean section
▪ Neonatal intensive care unit (NICU) admissions
▪ Infant growth/weight gain
▪ Major neonatal morbidities (as defined by the trial
authors)
For any outcomes reported as a composite measure,
we will extract all composite and individual outcomes as
reported in the studies, where available.
Setting
There will be no restrictions by type of setting.
Time frame
Studies will be selected that provide information about
interventions commenced during pregnancy and/or
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during birth. Measurement of outcomes will focus on
the perinatal period as defined by the Australian Insti-
tute of Health and Welfare, as 20 weeks of pregnancy to
28 days after birth [24].
Study designs
We will include randomised controlled trials (RCTs)
(including cluster RCTs) and non-randomised studies
including controlled before-and-after studies, inter-
rupted time-series studies and prospective comparative
cohort studies. Case-control studies, crossover trials and
cross-sectional studies will be excluded.
Information sources
We will perform a systematic literature search using the
following electronic bibliographic databases: PubMed,
Embase, The Cochrane Library, CINAHL and WHO
Global Health Library. Collections such as POPLINE
database and CABI Global Health will also be searched.
We will conduct handsearches of journals or conference
proceedings from the reference lists of retrieved studies.
No language or date restrictions will be applied.
Abstracts and full-length articles will be obtained for
each citation. Reference lists of included studies and
relevant reviews will be scanned to ensure coverage of
the literature. The search will only include peer-
reviewed publications.
Search strategy
The specific search strategies were developed by the
primary author and an experienced clinical research
librarian, with input from all authors. An electronic
search using subject headings and all fields for keywords
will be conducted to avoid missing non-indexed con-
cepts. Literature searches will be re-run just before final
analyses and further studies retrieved for inclusion.
Search terms and search strategy example are provided
in Additional file 2.
Study records
Data management
Reference management software EndNote will be used
to organise articles describing studies identified in the
literature search. Search results from different electronic
databases will be combined in a single EndNote library
and duplicate records of the same reports will be
removed.
Remaining literature search results will be uploaded to
Covidence [25], a web-based software platform that sup-
ports citation screening and facilitates collaboration
among multiple authors. The team will develop and test
screening questions and forms based on the review in-
clusion and exclusion criteria. Citation abstracts and full
text articles will be uploaded to the Covidence software.
Selection process
Two reviewers will independently screen the title and
abstract of retrieved citations to determine if they meet
inclusion and exclusion criteria, using the Covidence
software. If there is a concern about inclusion, the
abstract will be reviewed by a third author to determine
if it meets the inclusion criteria. If necessary, study
authors will be contacted up to two times to resolve
questions about eligibility. Reasons will be recorded for
excluding trials.
Studies will be included only once for evaluation, and
multiple publications from the same study will be
reported. The publication which most comprehensively
describes the results will be used as a primary reference.
Review authors will not be blind to the journal titles,
study authors or institutions, as several studies have
found that such masking is of limited value in study
selection for systematic reviews [26, 27]. For selected
studies, full articles will be obtained and read by two
authors to confirm that they meet inclusion criteria. Any
differences of opinion between two reviewers will be
resolved by a third review author and consensus. A
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) flow-diagram [28] will sum-
marise the inclusion and exclusion of studies.
Data collection process
Two authors will independently extract outcome data
using standardised forms, once studies are selected. Data
extraction will include study objective, study design, in-
clusion and exclusion criteria, data sources, study period,
methodology, population size, intervention details, dur-
ation, intensity and effects and outcomes. A standardised
form will be designed to extract data required for the
quality assessment and evidence synthesis, and summary
tables will be populated. Each author will thoroughly
review the summary tables for relevance and accuracy.
Any differences of opinion between two reviewers will
be resolved by a third review author and consensus. If
necessary, study authors will be contacted up to two
times to provide further details. Data will be entered into
Review Manager software [29] and checked for accuracy.
Assessment of risk of bias
Quality assessment
Risk of bias for randomised trials will be assessed using
established guidelines provided in the Cochrane Hand-
book for Systematic Reviews of Interventions [30]. Six
domains are covered in this guideline: selection bias,
performance bias, detection bias, attrition bias, reporting
bias and other bias. Explicit judgements will be made
about whether studies are at high risk of bias, according
to the criteria given in the handbook [30]. The likely
magnitude and direction of the bias, and whether it is
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likely to have impacted findings, will be assessed. The
impact of the level of bias identified will be explored
through undertaking sensitivity analyses.
Quality assessment of non-randomised studies will be
based on the Risk of Bias in Non-randomised Studies-of
Interventions (ROBINS-I) assessment tool [31].
Two reviewers will independently assess the risk of
bias of included studies. Any disagreements between the
review authors over the risk of bias in particular studies
will be resolved by discussion, with involvement by a
third review author where necessary.
Assessment of the body of evidence—the GRADE
approach
Quality of the evidence will be evaluated using the
Grades of Recommendation, Assessment, Development
and Evaluation (GRADE) approach [32]. The GRADE
approach uses five considerations (study limitations,
consistency of effect, imprecision, indirectness and pub-
lication bias) to assess the quality of the body of
evidence for specific outcomes. The evidence can be
downgraded from ‘high quality’ by one level for serious
(or by two levels for very serious) limitations, depending
on assessments for risk of bias, indirectness of evidence,
serious inconsistency, imprecision of effect estimates or
potential publication bias.
“Summary of findings” tables
GRADE Profiler [33] will be used to import data from
Review Manager software [29] in order to create a “Sum-
mary of Findings” table. A summary of intervention
effect and a measure of quality according to the GRADE
approach [34] will be presented as tables for the follow-
ing outcomes of interest:
1. Maternal behaviours achieved (primary outcome)
2. Maternal knowledge (about the health topic that is
the target of the intervention)
3. Maternal evaluation of the intervention
4. Maternal psychosocial outcomes
5. Health service utilisation
6. Perinatal mortality
7. Major neonatal morbidities
Measures of treatment effect
Randomised control trials (RCTs) and non-RCTs will be
analysed separately. For intervention studies including
randomised control trials, results will be presented as
summary risk ratios (RR) with 95% confidence intervals
(CI) for dichotomous outcomes. For continuous data,
the mean difference will be used if outcomes are mea-
sured in the same way between trials. The standardised
mean difference will be used to combine trials that
measure the same outcome, but use different methods.
For cohort studies, effect estimates will be presented
where possible as percentages, relative risk (RR) or odds
ratios (OR) with 95% CIs, or adjusted RR or OR if
reported with 95% CIs, in tabular format based on study
type; narrative synthesis will summarise the studies. Ran-
dom effects meta-analyses will be performed, accounting
for variation of diverse studies.
Unit of analysis issues
Cluster-randomised trials will be included in analyses
along with individually randomised trials. Sample sizes
will be adjusted using an estimate of the intracluster
correlation co-efficient (ICC) derived from the included
trial (if possible), from a similar trial or from a study of
a similar population. If ICCs are used from other
sources, this will be reported and sensitivity analyses
conducted to investigate the effect of variation in the
ICC. If both cluster-randomised and individually rando-
mised trials are identified, relevant information will be
synthesised. It will be considered reasonable to combine
the results from both if there is little heterogeneity
between the study designs and the interaction between
the effect of intervention and the choice of randomisa-
tion unit is considered to be unlikely.
Heterogeneity in the randomisation unit will also be
acknowledged, and a sensitivity analysis performed to
investigate the effects of the randomisation unit.
Dealing with missing data
For included studies, levels of attrition will be noted.
The impact of including studies with high levels of miss-
ing data will be explored in the overall assessment of
treatment effect by using sensitivity analysis.
For all outcomes, analyses will be carried out, as far as
possible, on an intention-to-treat basis, i.e. with attempts
to include all participants randomised to each group in
the analyses (for RCTs), and all participants analysed in
the group to which they were allocated, regardless of
whether or not they received the allocated intervention.
The denominator for each outcome in each RCT will be
the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of heterogeneity
Heterogeneity between studies will be assessed by
comparison of study settings, populations and design,
supplemented with the I2 statistic. Where data is not
presented in such a way that inclusion in meta-analysis
is possible, or where only one study is identified for a
risk factor, results of individual studies will be presented.
Statistical heterogeneity will be assessed in each meta-
analysis using the T2, I2 and Chi2 statistics. We will
regard heterogeneity as substantial if I2 is greater than
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30% and either T2 is greater than zero or there is a low
P value (<0.10) in the Chi2 test for heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis,
reporting biases (such as publication bias) will be inves-
tigated using funnel plots. Funnel plot asymmetry will
be assessed visually. If asymmetry is suggested by a visual
assessment, exploratory analyses will be performed to
investigate further.
Data synthesis
Statistical analyses will be carried out using the Review
Manager (RevMan) software [29]. Fixed-effect meta-
analysis will be used for combining data where it is
reasonable to assume that studies are estimating the
same underlying treatment effect: i.e. where trials are
examining the same intervention, and the trials’ popula-
tions and methods are judged sufficiently similar.
If there is clinical heterogeneity sufficient to expect
that the underlying treatment effects differ between tri-
als, or if substantial statistical heterogeneity is detected,
random-effects meta-analysis will be used to produce an
overall summary, if an average treatment effect across
trials is considered clinically meaningful. The random-
effects summary will be treated as the average range of
possible treatment effects and clinical implications of
treatment effects differing between trials will be dis-
cussed. If the average treatment effect is not clinically
meaningful, trials will not be combined.
If random-effects analyses are used, the results will be
presented as the average treatment effect with 95% con-
fidence intervals, and the estimates of T2 and I2. Where
studies have used the same type of intervention and
comparator, with the same outcome measures, results
will be pooled using random-effects meta-analysis, with
standardised mean differences for continuous outcomes
and risk ratios for binary outcomes. If formal pooling is
inappropriate for analysis, data synthesis will employ a
narrative and tabular approach.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses will be performed according to the
type of comparator, if studies permit.
Separate comparisons and analyses for primary and
secondary outcomes will be performed where possible,
and analyses will be performed for the following
subgroups, if studies permit:
1. Low-resource versus high-resource settings.
2. Maternal characteristics by age and parity.
3. Approach to information available on-demand used
by mobile application (“pull” communication), or
timed delivery of information (“push
communication”).
If substantial heterogeneity is identified, it will be
investigated using subgroup analyses and sensitivity ana-
lyses. Authors will consider whether an overall summary
is meaningful, and if it is, use random-effects analysis to
produce it.
Subgroup differences will be assessed by interaction
tests available within RevMan [29]. Results of subgroup
analyses will quote the Chi2 statistic and P value, and
the interaction test I2 value.
Sensitivity analysis
Sensitivity analyses will be carried out to explore the ef-
fects of high attrition rates with studies showing attrition
greater than 20% excluded from the analyses in order to
assess whether there are any differences to the overall
result. Where ICCs are used, sensitivity analyses will
explore the effects of variation in ICC values and in the
randomisation unit (i.e. individual versus cluster).
Discussion
Millions of women, across many countries, utilise mobile
applications regularly during pregnancy, for purposes of
gathering information, data tracking, information shar-
ing, education and reassurance. This systematic review is
the first to assess the effects of mobile application inter-
ventions during pregnancy on influencing healthy mater-
nal behaviour and improving perinatal outcomes. Results
of this systematic review could contribute to decision-
making by health systems, hospitals and clinicians about
whether integration of mobile applications might influ-
ence the knowledge and behaviour of women in their
care, particularly those demonstrating risk factors.
Additional files
Additional file 1: PRISMA-P checklist. This checklist includes a list of
recommended items to include in a systematic review protocol. (DOCX 28 kb)
Additional file 2: Search terms and search strategy. This search strategy
tailored for PubMed will be adapted for each database. (DOCX 17 kb)
Abbreviations
Apps: Mobile applications; CI: Confidence interval; GDM: Gestational diabetes
mellitus; GRADE: Grades of recommendation, assessment, development and
evaluation; ICC: Intracluster correlation co-efficient; LGA: Large for gestational
age; MESH: Medical subject headings; OR: Odds ratio; PRISMA-P: Preferred
Reporting Items for Systematic Reviews and Meta-Analysis Protocols;
PROSPERO: International Prospective Register of Systematic Reviews;
RCT: Randomised controlled trial; ROBINS-I: Risk of bias in non-randomised
studies–of interventions assessment tool; RR: Risk ratio; SGA: Small for
gestational age; WHO: World Health Organization
Acknowledgements
The Methods—Measures of Treatment Effect section of this protocol is
based on a standard template used by Cochrane Pregnancy and Childbirth
Review Group, with modification by review authors.
Daly et al. Systematic Reviews  (2017) 6:26 Page 6 of 8
Funding
This systematic review protocol is part of the corresponding author’s
doctoral thesis, which is funded through an Australian Government Research
Training Program Scholarship at the University of Queensland and Frank Clair
Scholarship at Mater Research Institute, Australia.
Internal sources
The following institutions have provided support to review authors to
allow them to undertake this review:
▪ Mater Research Institute, The University of Queensland, Australia
▪ South Australian Health and Medical Research Institute (SAHMRI),
Adelaide, Australia
▪ School of Psychology and Public Health, La Trobe University,
Australia
Supporting institutions are not involved in aspects of the project such as
design of the protocol and analysis plan, data collection and analyses,
data interpretation or publication of study results.
External sources
No external sources of support have been provided for this review.
Availability of data and materials
The datasets generated and/or analysed during the current study shall be
available from the corresponding author on reasonable request.
Authors’ contributions
LMD and VF conceptualized the review in consultation with the co-reviewers.
LMD wrote the first draft of this protocol with substantial inputs from all
authors. LMD, VF and DH will contribute to the literature search, screening,
collection and analysis of data for all the included interventions, with close
consultation from PM and FB. All authors will provide input, review and
finalize the paper before dissemination. The corresponding author is the





The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Amendments
Any updates or amendments to this protocol will be described in a table
including the date of each amendment, description of the change and
rationale for the change. The PROSPERO register will remain updated with
the protocol and amendments.
Author details
1Mater Research Institute, The University of Queensland, South Brisbane,
QLD, Australia. 2School of Psychology and Public Health, La Trobe University,
Bundoora, VIC, Australia. 3Healthy Mothers, Babies and Children’s Theme,
SAHMRI, Adelaide, SA, Australia. 4School of Public Health, The University of
Queensland, Herston, QLD, Australia.
Received: 11 November 2016 Accepted: 26 January 2017
References
1. Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index
and the risk of fetal death, stillbirth, and infant death: a systematic review
and meta-analysis. JAMA. 2014;311:1536–46.
2. Marufu TC, Ahankari A, Coleman T, Lewis S. Maternal smoking and the risk of
still birth: systematic review and meta-analysis. BMC Public Health. 2015;15:239.
3. Flenady V, Middleton P, Smith GC, Duke W, Erwich JJ, Khong TY, Neilson J,
Ezzati M, Koopmans L, Ellwood D, et al. Stillbirths: the way forward in
high-income countries. Lancet. 2011;377:1703–17.
4. Saastad E, Tveit JV, Flenady V, Stray-Pedersen B, Fretts RC, Bordahl PE,
Froen JF. Implementation of uniform information on fetal movement in a
Norwegian population reduced delayed reporting of decreased fetal
movement and stillbirths in primiparous women - a clinical quality
improvement. BMC Res Notes. 2010;3:2.
5. Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D,
Flenady V, Froen JF, Qureshi ZU, Calderwood C, et al. Stillbirths: rates,
risk factors, and acceleration towards 2030. Lancet. 2016;387:587–603.
6. O’Higgins A, Murphy OC, Egan A, Mullaney L, Sheehan S, Turner MJ.
The use of digital media by women using the maternity services in a
developed country. Ir Med J. 2014;107:313–5.
7. Asiodu IV, Waters CM, Dailey DE, Lee KA, Lyndon A. Breastfeeding and use
of social media among first-time African American mothers. J Obstet
Gynecol Neonatal Nurs. 2015;44:268–78.
8. Higgs ES, Goldberg AB, Labrique AB, Cook SH, Schmid C, Cole CF, Obregon
RA. Understanding the role of mHealth and other media interventions for
behavior change to enhance child survival and development in low- and
middle-income countries: an evidence review. J Health Commun. 2014;19
Suppl 1:164–89.
9. Ledford CJ, Canzona MR, Cafferty LA, Hodge JA. Mobile application as a
prenatal education and engagement tool: a randomized controlled pilot.
Patient Educ Couns. 2016;99:578–82.
10. Free C, Phillips G, Galli L, Watson L, Felix L, Edwards P, Patel V, Haines A.
The effectiveness of mobile-health technology-based health behaviour
change or disease management interventions for health care consumers:
a systematic review. Plos Med. 2013;10:e1001362.
11. Agarwal S, Labrique A. Newborn health on the line: the potential mHealth
applications. JAMA. 2014;312:229–30.
12. Snell J, Cohen P. Apple opens iTunes App Store. In Macworld. San Francisco:
IDG Consumer & SMB; 2008.
13. Thomas GM, Lupton D. Threats and thrills: pregnancy apps, risk and
consumption. Health Risk Soc. 2016;17:495–509.
14. Jahns R. mHealth app developers economics. Germany: The State of the Art
of mHealth App Publishing; 2014.
15. Lupton D, Pedersen S. An Australian survey of women’s use of pregnancy
and parenting apps. Women Birth. 2016;29:368–75.
16. Hearn L, Miller M, Fletcher A. Online healthy lifestyle support in the
perinatal period: what do women want and do they use it? Aust J Prim
Health. 2013;19:313–8.
17. Wellde PT, Miller LA. There’s an app for that!: new directions using social
media in patient education and support. J Perinat Neonatal Nurs.
2016;30:198–203.
18. Daly LM. Apps and opps: mobile applications and opportunities for
longitudinal data collection across the reproductive lifespan. In Australian
Longitudinal Study of Women’s Health (ALSWH) Scientific Meeting.
Newcastle: ALSWH Scientific Meeting; 2016.
19. O’Donnell BE, Lewkowitz AK, Vargas JE, Zlatnik MG. Examining pregnancy-
specific smartphone applications: what are patients being told? J Perinatol.
2016;36:802–7.
20. Vodopivec-Jamsek V, de Jongh T, Gurol-Urganci I, Atun R, Car J. Mobile
phone messaging for preventive health care. Cochrane Database Syst Rev.
2012;12:Cd007457.
21. Horvath T, Azman H, Kennedy GE, Rutherford GW: Mobile phone text
messaging for promoting adherence to antiretroviral therapy in patients
with HIV infection. Cochrane Database Syst Rev 2012;(3):Cd009756.
22. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P,
Stewart LA. Preferred reporting items for systematic review and
meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
BMJ. 2015;349:g7647.
23. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P,
Stewart LA. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;2015(4):1–9.
24. Australian Institute of Health and Welfare. Metadata online registry
(METeOR). Canberra: AIHW; 2016.
25. Veritas Health Innovation. Melbourne: Covidence systematic review
software; 2016.
26. Berlin JA. Does blinding of readers affect the results of meta-analyses? University
of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350:185–6.
27. University of York. Systematic Reviews: CRD’s guidance in undertaking
reviews in health care. Section 1.3.2.1: Masking/blinding. Thirdth ed.
New York: Centre for Reviews and Dissemination; 2009.
Daly et al. Systematic Reviews  (2017) 6:26 Page 7 of 8
28. Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. Plos Med. 2009;6:e1000097.
29. RevMan. Review Manager. 53rd ed. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration; 2014.
30. Higgins J, Green S: Cochrane Handbook for Systematic Reviews of
Interventions, Version 5.1.0. The Cochrane Collaboration. 2011. www.
handbook.cochrane.org.
31. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M,
Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for
assessing risk of bias in non-randomised studies of interventions. BMJ.
2016;355:i4919.
32. Schunemann H, Brozek J, Guyatt G, Oxman AD: GRADE Handbook:
handbook for grading the quality of evidence and the strength of
recommendations using the GRADE approach. 2013. http://gdt.
guidelinedevelopment.org/app/handbook/handbook.html.
33. GRADEpro: GRADEpro. Hamilton: McMaster University; 2014.
34. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J,
Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines: 3.
Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Daly et al. Systematic Reviews  (2017) 6:26 Page 8 of 8
